ArticleCerebellum (London, England)2026
Cerebellar Involvement in Immune-Mediated Pediatric Acute Ataxia: Clinical Spectrum, MRI Findings, and Predictors of MOG Antibody Positivity.
Article in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Acute ataxia is a common pediatric neurological presentation with diverse etiologies. While autoimmune mechanisms are increasingly recognized, the spectrum of autoimmune cerebellar ataxia in children remains poorly characterized. This study aimed to systematically compare the clinical, neuroimaging, and laboratory features of children with immune-mediated ataxia against seronegative controls, with particular focus on cerebellar involvement and predictors of MOG antibody positivity. This retrospective case-control study enrolled 73 children with acute ataxia who tested positive for neural autoantibodies or CSF oligoclonal bands (OCBs), and 59 seronegative controls. The immune-mediated cohort included subgroups with MOG, NMDAR, GD1b, MBP antibodies, or isolated OCBs. Demographic, clinical, neuroimaging, and laboratory data were analyzed. Multivariate logistic regression identified independent predictors of MOG antibody positivity. Immune-mediated patients exhibited higher acute mRS scores (3.07 vs. 2.63, p = 0.003), more frequent lethargy / altered sensorium (30.1% vs. 10.2%, p = 0.005), and higher relapse rates (15% vs. 0%, p = 0.002) than seronegative controls. Cerebellar MRI abnormalities were observed in 42.8% of MOG-positive patients and 77.7% of OCB-positive patients. MOG-positive patients (n = 20) had more severe encephalopathy and multifocal MRI lesions involving cerebral hemispheres, brainstem, and cerebellum compared to OCB-positive (n = 38) and seronegative groups. Multivariate regression identified younger age (OR = 0.718), higher acute mRS score (OR = 5.917), and cranial MRI abnormalities (OR = 27.746) as independent predictors of MOG positivity (all p < 0.01). Pediatric autoimmune cerebellar ataxia encompasses a heterogeneous spectrum. MOG antibody-associated ataxia represents a severe encephalitic syndrome with widespread MRI lesions including frequent cerebellar involvement, while isolated OCB positivity defines a clinically mild but relapsing-prone subgroup with predominant cerebellar MRI findings. Early recognition of clinical and imaging "red flags" enables timely risk stratification and targeted immunomodulatory intervention in children with autoimmune cerebellar ataxia.
Indexed as
Identifiers
42277347What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.